LYOS : INSERM UMR 1033, Université de Lyon, France.

Pathophysiology, Diagnosis & Treatments of Musculoskeletal Disorders


Musculoskeletal disorders, including bone diseases, osteoarthritis, inflammatory diseases, bone metastasis and sarcopenia are responsible for a major disease burden worldwide. There remains an important gap in terms of pathophysiology understanding, diagnosis and therapy that we address. We conduct research in this area from bench to bedsite, thanks to a wide platform including cell biology, animal models, biomechanics studies, epidemiology and clinical research.

Our scientific strategy hinges on 3 teams.

Team 1’s major objectives are to improve the prediction of fracture risk in men and women with osteoporosis. The relations between bone and certain chronic diseases will be also studied. It has become obvious (albeit little understood) that bone quality is influenced by chronic diseases and, conversely, that bone remodeling participates in the genesis of chronic diseases.

Team 2’s main objectives are to identify the underlying molecular mechanisms governing the nesting of tumour cells in the bone marrow and those that favour the formation of medullary micrometastases, the prelude required for bone metastasis formation. Additionally, new biological markers of early relapse of cancer in bone will be developed and novel therapeutics are being tested in animal models of malignant bone diseases.

Team 3’s main objectives are to study the pathophysiological role of bioactive lipids (lysophosphatidic acid, leukotrienes), calcium phosphate metabolism in rare diseases, benign (osteoporosis, rheumatoid arthritis) and cancerous (bone metastasis) bone pathologies.

Roland Chapurlat


Bone, joint and muscle chronic diseases

Pascale Cohen

Pascale COHEN

Bone, Cancer and Metastasis

Olivier Peyruchaud


Bone and Joint Pathophysiology: Bioactive lipids and mineral metabolism.

Short description
of the lab in figures:

  • Staff: 57
  • Basic and clinical scientists: 28
  • Research Engineers and Technicians: 18
  • Postdoctoral fellows and research students: 11

9 key most recent publications :

  • Auroux M, Merle B, Fontanges E, Duvert F, Lespessailles E, Chapurlat R. The disability associated with hand osteoarthritis is substantial in a cohort of post-menopausal women: the QUALYOR study. Osteoarthritis Cartilage. 2022 Nov;30(11):1526-1535.
  • Chapurlat R, Gensburger D, Trolliet C, Rouanet S, Mehsen-Cetre N, Orcel P. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial. Bone. 2022 Apr;157:116343. doi: 10.1016/j.bone.2022.116343.
  • Szulc P, Foesser D, Chapurlat R. High Cardiovascular Risk in Older Men with Poor Bone Microarchitecture-The Prospective STRAMBO Study. J Bone Miner Res. 2021 May;36(5):879-891.
  • F. Pantano, M. Croset, K. Driouch, N. Bednarz-Knoll, M. Iuliani, G. Ribelli, E. Bonnelye, H. Wikman, S. Geraci, F. Bonin, S. Simonetti, B. Vincenzi, S.S. Hong, S. Sousa, K. Pantel, G. Tonini, D. Santini, P. Clezardin, Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions, Oncogene 40(7) (2021) 1284-1299.
  • A. Bellanger, D.T. Le, J. Vendrell, A. Wierinckx, L.S. Pongor, J. Solassol, J. Lachuer, P. Clezardin, B. Gyorffy, P.A. Cohen, Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer, Front Oncol 11 (2021) 647269.
  • E. Massy, J.C. Rousseau, M. Gueye, E. Bonnelye, M. Brevet, L. Chambard, M. Duruisseaux, O. Borel, C. Roger, R. Guelminger, J.B. Pialat, E. Gineyts, L. Bouazza, M. Millet, J.M. Maury, P. Clezardin, N. Girard, C.B. Confavreux, Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma, J Bone Oncol 29 (2021) 100364.
  • Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nature Reviews. Nephrology. 2023;19(3):194-211. Epub 20230105. doi: 10.1038/s41581-022-00661-1. PubMed PMID: 36604599.
  • Méaux MN, Alioli C, Linglart A, Lemoine S, Vignot E, Bertholet-Thomas A, et al. X-linked hypophosphatemia, not only a skeletal disease but also a chronic inflammatory state. J Clin Endocrinol Metab. 2022. Epub 20220916. doi: 10.1210/clinem/dgac543. PubMed PMID: 36112422.
  • Saier L, Ribeiro J, Daunizeau T, Houssin A, Ichim G, Barette C, et al. Blockade of Platelet CysLT1R Receptor with Zafirlukast Counteracts Platelet Protumoral Action and Prevents Breast Cancer Metastasis to Bone and Lung. Int J Mol Sci. 2022;23(20). Epub 20221013. doi: 10.3390/ijms232012221. PubMed PMID: 36293074; PubMed Central PMCID: PMCPMC9603002.